SignalXSignalX

ATRC AtriCure, Inc.

FY2025 10-K
Filed: Feb 19, 2026
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR
AtriCure, Inc. Overview

AtriCure, Inc. (ATRC) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business model centers on medical devices for cardiac surgery and related treatments
  • • Enhanced emphasis on cybersecurity risk management aligning with NIST Cybersecurity Framework and Zero Trust principles this fiscal year
+3 more insights

Management Discussion & Analysis

  • • Revenue $534.5M, up 14.9% YoY ($465.3M in 2024); growth driven by pain management (+32.5%), open ablation (+16.3%), appendage management (+17.5%), minimally invasive ablation declined (−31.2%)
  • • Gross margin 75.0% vs 74.7%, up 29 basis points; operating margin loss improved to −1.8% vs −8.6%; net loss narrowed to $11.4M (−2.1%) vs $44.7M (−9.6%)
+3 more insights

Risk Factors

  • • No specific or timely regulatory or legal risks detailed beyond general cybersecurity oversight frameworks
  • • No geopolitical or macroeconomic threats identified with concrete exposure details
+3 more insights

Get deeper insights on AtriCure, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available